Jim Simons Crinetics Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$25.62 - $37.07 $3.89 Million - $5.63 Million	-152,000 Reduced 92.85%	11,700 $416,000
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $2.61 Million - $5.01 Million	163,700 New	163,700 $4.87 Million
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $977,419 - $1.2 Million	63,100 New	63,100 $1.16 Million
Q2 2022 Aug 12, 2022	BUY	$16.49 - $27.64 $1.42 Million - $2.39 Million	86,400 New	86,400 $1.61 Million
Q1 2021 May 13, 2021	SELL	$13.3 - $17.55 $339,150 - $447,525	-25,500 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$12.08 - $17.46 $308,040 - $445,230	25,500 New	25,500 $360,000
Q3 2020 Nov 13, 2020	SELL	$13.62 - $17.66 $484,872 - $628,696	-35,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$13.04 - $23.23 $464,223 - $826,988	35,600 New	35,600 $624,000

241

80M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.12B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.